Dynavax Technologies
Dynavax, a US biopharmaceutical firm, develops and markets novel vaccines, including a hepatitis B vaccine and COVID-19 research.
Founded
1996Dynavax, a US biopharmaceutical firm, develops and markets novel vaccines, including a hepatitis B vaccine and COVID-19 research.
Dynavax Technologies, founded in Berkeley, United States, is a commercial-stage biopharmaceutical company committed to developing and commercializing novel vaccines aimed at preventing infectious diseases. The company's core mission is to protect global health through innovative adjuvant technology. Dynavax's flagship product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for adults aged 18 and older. Additionally, Dynavax is advancing its CpG 1018™ adjuvant through various research collaborations and partnerships.
Notable figures associated with Dynavax include its dedicated team of scientists and executives who drive its mission forward. The company has garnered significant investment and support from the biopharmaceutical community. Key achievements include the successful commercialization of HEPLISAV-B® and the development of CpG 1018™ as a premier vaccine adjuvant. Dynavax's impact is marked by its contributions to public health, particularly in the prevention of hepatitis B and other infectious diseases through its innovative vaccine solutions.
Companies similar to Dynavax Technologies include Novavax, GeoVax Labs, Adjuvance Technologies and Sinovac Biotech.
Dynavax Technologies was founded in 1996.
Dynavax Technologies' headquarters is located in Berkeley, CA, US.
Dynavax Technologies' most recent funding round was for $200M (USD) in May 2021.
As of May 11, 2021, Dynavax Technologies has disclosed funding of $1.4B (USD). Undisclosed round amounts are excluded.
Dynavax Technologies has 351 employees as of Feb 6, 2024.
Sinovac Biotech
